Trials / Completed
CompletedNCT02561585
LEO 124249 Ointment in the Treatment of Alopecia Areata
Efficacy of Twice Daily Applications of LEO 124249 Ointment 30mg/g for 12 Weeks to Subjects With Alopecia Areata
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.
Detailed description
The objectives of this clinical trial are to compare the efficacy of twice-daily topical LEO 124249 30 mg/g ointment with LEO 124249 ointment vehicle for 12 weeks in the treatment of hair loss in subjects with alopecia areata, to evaluate the safety of this treatment, to evaluate hair regrowth, to determine subject quality of life, and to explore disease mechanism and its biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 124249 | |
| OTHER | Vehicle |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2015-09-28
- Last updated
- 2025-03-06
- Results posted
- 2019-04-16
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02561585. Inclusion in this directory is not an endorsement.